经皮血管内动静脉瘘的系统评价聚合数据与个体参与者数据Meta分析
该系统评价与个体参与者数据Meta分析纳入18项研究共1863例患者,评估经皮血管内动静脉瘘(pAVF)的短期与中期安全性和有效性。pAVF与手术动静脉瘘(sAVF)在主要终点上无统计学显著差异,但pAVF的窃血综合征和伤口感染风险更低。Ellipsys装置的二期通畅率显著优于WavelinQ。
要点
- pAVF总体一期通畅率54.01%,二期通畅率87.27%,功能穿刺率79.94%。
- pAVF与sAVF的一期和二期通畅风险比分别为1.27和1.25,均 favoring sAVF 但无统计学显著差异。
- pAVF窃血综合征相对风险5.91、伤口感染相对风险4.19,均高于sAVF且达统计学显著。
核心结论
- pAVF与sAVF在任何主要终点上均未发现统计学显著差异,但pAVF显示窃血综合征和伤口感染风险降低。
- Ellipsys和WavelinQ装置的二期通畅率均令人满意,但Ellipsys较WavelinQ有统计学显著改善。
- WavelinQ的再干预率虽呈边缘性统计学不显著的劣势,但三分之一WavelinQ pAVF导致废弃。
- pAVF作为治疗方式的引入需要标准化定义调整和改进。
研究设计与样本
- 系统评价与聚合数据Meta分析,遵循PRISMA 2020和PRISMA-IPD 2015。
- 纳入18项研究,共1863例患者。
- 对比较pAVF与sAVF的研究进行两阶段个体参与者数据Meta分析,评估一期和二期通畅率。
主要发现
- pAVF总体一期通畅率54.01%(95%CI 40.69-66.79),二期通畅率87.27%(95%CI 81.53-91.42),功能穿刺率79.94%(95%CI 65.94-89.13),废弃率15.58%(95%CI 7.77-28.79)。
- pAVF总体技术成功率97.08%(95%CI 95.66-98.04),成熟率82.13%(95%CI 71.64-89.32),每人年再干预率0.80(95%CI 0.34-1.47),平均成熟时间58天(95%CI 36.64-92.82)。
- 仅WavelinQ和Ellipsys显示统计学显著差异的终点为二期通畅率81.36%(95%CI 76.15-85.65) vs 92.12%(95%CI 87.94-94.93)和废弃率32.54%(95%CI 22.23-44.87) vs 11.13%(95%CI 4.82-23.65)。
- pAVF与sAVF的一期通畅风险比1.27(95%CI 0.61-2.67),二期通畅风险比1.25(95%CI 0.87-1.80),favoring sAVF。
- pAVF与sAVF的窃血综合征相对风险5.91(95%CI 1.12-31.12),伤口感染相对风险4.19(95%CI 1.04-16.88),均达统计学显著。
关键数值与推荐
- pAVF总体一期通畅率54.01%(95%CI 40.69-66.79),二期通畅率87.27%(95%CI 81.53-91.42),功能穿刺率79.94%(95%CI 65.94-89.13),废弃率15.58%(95%CI 7.77-28.79)。
- pAVF总体技术成功率97.08%(95%CI 95.66-98.04),成熟率82.13%(95%CI 71.64-89.32),每人年再干预率0.80(95%CI 0.34-1.47),平均成熟时间58天(95%CI 36.64-92.82)。
- Ellipsys vs WavelinQ的二期通畅率92.12%(95%CI 87.94-94.93) vs 81.36%(95%CI 76.15-85.65),废弃率11.13%(95%CI 4.82-23.65) vs 32.54%(95%CI 22.23-44.87)。
- pAVF vs sAVF的一期通畅风险比1.27(95%CI 0.61-2.67),二期通畅风险比1.25(95%CI 0.87-1.80)。
- pAVF vs sAVF的窃血综合征相对风险5.91(95%CI 1.12-31.12),伤口感染相对风险4.19(95%CI 1.04-16.88)。
临床怎么用
- 原文结论未据此给出具体临床推荐,仅指出pAVF与sAVF主要终点无统计学显著差异,pAVF窃血综合征和伤口感染风险降低。
- 原文结论指出pAVF作为治疗方式的引入需要标准化定义调整和改进。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the short-term and mid-term safety and efficacy of percutaneous endovascular arteriovenous fistula (pAVF) creation. METHODS: A systematic search was implemented corresponding to the PRISMA 2020 and the PRISMA for individual participant data (IPD) systematic reviews 2015. Aggregated data from the included studies were obtained and meta-analyzed regarding both the overall pAVF efficacy and the comparison of pAVF with surgical AVF (sAVF). We performed a two-stage IPD meta-analysis for studies comparing pAVF and sAVF regarding primary and secondary patency. Primary end points included primary patency, secondary patency, and functional cannulation. RESULTS: Eighteen studies with 1863 patients were included. The overall pAVF, primary patency, secondary patency, functional cannulation and abandonment rates were 54.01% (95% confidence interval [CI], 40.69-66.79), 87.27% (95% CI, 81.53-91.42), 79.94% (95% CI, 65.94-89.13), and 15.58% (95% CI, 7.77-28.79), respectively. The overall pAVF, technical success, maturation, reintervention per person-years and mean time to maturation rates were 97.08% (95% CI, 95.66-98.04), 82.13% (95% CI, 71.64-89.32), 0.80 (95% CI, 0.34-1.47), and 58 days (95% CI, 36.64-92.82), respectively. Secondary patency and pAVF abandonment rates where the only end points were WavelinQ and Ellipsys displayed statistically significant differences of 81.36% (95% CI, 76.15-85.65) versus 92.12% (95% CI, 87.94-94.93) and 32.54% (95% CI, 22.23-44.87) versus 11.13% (95% CI, 4.82-23.65). An IPD meta-analysis of hazard ratios for primary and secondary patency between pAVF and sAVF were 1.27 (95% CI, 0.61-2.67) and 1.25 (95% CI, 0.87-1.80), favoring sAVF. Statistically significant difference between pAVF and sAVF were solely depicted for steal syndrome relative risk of 5.91 (95% CI, 1.12-31.12) and wound infections relative risk of 4.19 (95% CI, 1.04-16.88). Plotting of pAVF smoothed hazard estimate displayed an upsurge in the probability of primary patency failure at 1 month after the intervention. CONCLUSIONS: Although we failed to identify statistically significant differences between pAVF and sAVF regarding any of the primary end points, pAVF displayed a decreased risk for steal syndrome and wound infection. Although both the Ellipsys and WavelinQ devices displayed satisfactory secondary patency rates, Ellipsys demonstrated a statistically significant improved rate compared with WavelinQ. Additionally, and despite the borderline statistically insignificant inferior reintervention rate displayed by WavelinQ, one in three WavelinQ pAVFs resulted in abandonment. The introduction of pAVF as a treatment modality calls for standardized definition adjustment and improvement.
引用
- Bontinis A, Bontinis V, Koutsoumpelis A, et al. A systematic review aggregated data and individual participant data meta-analysis of percutaneous endovascular arteriovenous fistula. J Vasc Surg. 2022. PMID: 36328141. doi:10.1016/j.jvs.2022.10.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。